Cancer Family
Salivary Gland Neoplasm
CI-CAN-00000343Explore in graph →
Non-malignant74 active trials13 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000343Explore in graph →
Clinical trials
267 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845097 | Phase II Trial Comparing Stereotactic Body Radiotherapy Versus Active Surveillance for Oligometastatic Adenoid Cystic Carcinoma | not yet recruiting | Phase 2 | 90 | All India Institute of Medical SciencesOTHER | 0 | Sep 28, 2026 |
| clinicaltrials |
| NCT04325828 | A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma(YATAGARASU) | active not recruiting | Phase 2 | 31 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04858334 | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | recruiting | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 3 | Sep 25, 2026 | clinicaltrials |
| NCT06781567 | Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma(HG146) | recruiting | Phase 2 | 140 | HitGen Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07162480 | Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I) | recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT07815522 | Abiraterone With Dalpiciclib in Salivary Gland Carcinoma | recruiting | Phase 2 | 36 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05774899 | CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC | recruiting | Phase 1 / Phase 2 | 32 | Michael J. Dennis, MDOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT05286827 | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05010629 | 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma | active not recruiting | Phase 2 | 32 | Glenn J. HannaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06891560 | A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma | recruiting | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05669664 | Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers | active not recruiting | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04119453 | A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) | terminated | Phase 2 | 80 | Elevar TherapeuticsINDUSTRY | 2 | Jul 30, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT07522879 | A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma(MRG003-SACC) | recruiting | Phase 2 | 40 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05075980 | Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study | active not recruiting | Phase 2 | 174 | Mayo ClinicOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05884320 | Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07521670 | Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)(STRAP) | not yet recruiting | Phase 2 | 68 | National Cancer Centre, SingaporeOTHER | 4 | Jul 15, 2026 | clinicaltrials |
| NCT03781986 | APG-115 in Salivary Gland Cancer Trial | active not recruiting | Phase 1 / Phase 2 | 41 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03942653 | Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma | active not recruiting | Phase 2 | 20 | Manish PatelOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07682675 | Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck(ZANACC) | not yet recruiting | Phase 2 | 51 | UNICANCEROTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05377996 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06118086 | Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma | recruiting | Phase 1 / Phase 2 | 125 | Remix TherapeuticsINDUSTRY | 2 | Jun 24, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04895735 | MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer | active not recruiting | Phase 2 | 45 | Mayo ClinicOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT02780310 | Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma | active not recruiting | Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07616141 | Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma(NAET4-SNACC) | not yet recruiting | Phase 2 | 76 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06054178 | Identification of Nerves Using Fluorescein Sodium | completed | Phase 2 | 8 | Stanford UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07320508 | Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study(EIC-SNACC) | recruiting | Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05074940 | Amivantamab in Adenoid Cystic Carcinoma | active not recruiting | Phase 2 | 21 | Trisha Wise-DraperOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04870762 | Customized 3D Printed Oral Stents During Head and Neck Radiotherapy | recruiting | Phase 2 | 119 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04620187 | Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas | recruiting | Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05694819 | Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY) | completed | Phase 2 | 57 | National Cancer Center Hospital EastOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05924256 | A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing | active not recruiting | Phase 2 | 88 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06145308 | Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing | recruiting | Phase 2 | 39 | Peking Union Medical CollegeOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07464366 | The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study(TSEMPRMSGC) | recruiting | Phase 2 | 90 | Ji DongmeiOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT03360890 | Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors(iPRIME) | active not recruiting | Phase 2 | 46 | University of ChicagoOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT00939627 | Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02047474 | Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer | completed | Phase 2 | 46 | Yale UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06322576 | 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma | terminated | Phase 2 | 1 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | active not recruiting | Phase 2 / Phase 3 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03172624 | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer | completed | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Dec 2, 2025 | clinicaltrials |
Data updated 15 hours agoSource updated Sep 29, 2026source: clinicaltrials